Introduction
Retinoic acid (RA), a natural derivative of vitamin A (retinol), is a major biological regulator operating during embryonic development and adult life. 1 It acts as a ligand for nuclear receptors (RARs) involved in the transcriptional regulation of specific genes. 2, 3 Retinoids induce a variety of biological responses including cell proliferation, growth arrest, cell differentiation and/or apoptosis. Interestingly, retinoids modulate these biological responses in both normal and tumor cells. [4] [5] [6] [7] [8] [9] [10] [11] The well-known pleiotropic effects of retinoids result primarily from the combinatorial action of their multiple receptors (RARs and RXRs), 12, 13 but also of other related receptors, partners in heterodimers (TRs, VDRs, PRs, PPARs and receptors with yet unidentified ligands, eg 'orphan' receptors), 14 (see RARs and RXRs act as ligand-dependent transrepressors of distinct transcription effectors such as AP-1 (first reported in . Interestingly, this inhibitory action on transactivation has proved to be reciprocal, further increasing the complexity of functional interaction. However, whether or not these cross-modulations result from direct or indirect molecular interaction is still debated (reviewed in Refs 22 and 23) . Several lines of evidence confirm the notion that nuclear receptors interact with other less-well characterized proteins to mediate their action on the regulation of gene expression, thus integrating diverse signalling pathways. A CREB-binding protein (CBP) integrator complex has been shown to act as a mediator in the transcriptional activation and inhibition of AP-1 by nuclear receptors (GRs, RARs). 24 Recent advances in the function of novel synthetic retinoids [25] [26] [27] which dissociate transactivation and repression ('dissociating retinoids') have increased the potentiality and selectivity of biological responses to retinoids that could be exploited for therapeutic purposes.
Acute promyelocytic leukemia (APL), a severe hematological disorder generated by a specific t(15;17) chromosomal translocation involving RAR␣, is the best-described pathology for which a retinoid-based therapy has been used successfully. 10, 11, 28 The molecular mechanisms behind the maturation response of APL cells to retinoids is even more complex than in other tumor cells and remains poorly defined 29 (for review see Ref. 30) . The fact that retinoids, at pharmacological concentrations, modulate RAR-dependent gene transcription and cell differentiation in a ligand-dependent manner by an action on heterodimeric complexes containing the fusion protein PML-RAR␣, suggests that this receptor contributes directly to restore a response altered by the t(15;17) translocation. 31, 32 However, other leukemia cell types with phenotypes closely related to APL bear other chromosomal translocations for which RAR␣ is fused to proteins distinct from PML (PLZF in t(11;17); nucleophosmin in t(5;17), 33, 34 but importantly these cells do not respond to retinoids by cell maturation. This points to the involvement of other mechanisms such as the action of repressors, 35 or alteration of PML-dependent signalling. PML exhibits anti-proliferative features and PML-RAR␣ may neutralize its anti-oncogenic function.
Recent findings indicate that membrane signaling play an important role in APL responses to retinoids. Those signallings include interferon, [36] [37] [38] and therefore, regulation of APL maturation may also depend on the Jak-STAT pathway. 39, 40 Other reports showed that retinoids, interferon and cAMP can act in synergy to induce morpho-functional maturation of the APL NB4 cells and expression of maturation-specific markers, but also apoptosis. [41] [42] [43] [44] [45] RARs have been shown to inhibit AP-1. In APL, the t(15;17) translocation produces a different situation where, in the presence of RA, the chimeric protein PML-RAR␣ cooperates with c-Jun and c-Fos and stimulates the transcription of reporter genes containing an AP-1 site. 46 Elucidation of the cascade of events leading to APL cell maturation by retinoids should benefit from the identification of RAR␣ targeted genes (primary targets), and also sets of genes that downstream are indirectly activated or repressed (secondary targets). Using a 'differential display' approach 47 we have identified new genes, RIG-E, 48 RIG-G, 49 and JEM -1, 50 that are modulated during retinoid-induced maturation of NB4 cells. These genes should serve as additional cell response markers; the elucidation of the mechanism of their transcriptional regulation should help to identify novel signalling pathways operating during APL cell maturation. Finally, understanding their function will provide novel clues on how retinoids efficiently reverse maturation defects in APL cells. JEM-1 is an interesting candidate gene to illustrate this strategy. Retinoid-induced maturation of NB4 cells upregulates the expression of JEM-1 mRNA, which has allowed its identification by PCR display, after 48 h of treatment. 50 JEM-1 is localized at the 1q24 chromosomal locus and encodes a novel 45 kDa nuclear protein, mainly characterized by the presence of a leucine repeat and several potential phosphorylation sites. A 3 kb JEM-1 transcript is induced in maturing NB4 cells, while it remains at a relatively high and steady level in NB4-R1 cells after treatment with retinoids. However, recent studies have shown a constitutive expression of JEM-1 in many normal and tumoral tissues. 51 In this work, we report the subcellular localization of the ectopically expressed Jem-1-1 protein in transfected HeLa and COS-7 cells. The observation that Jem-1-1 specifically localizes with AP-1 complexes in punctuated nuclear structures has orientated our investigation on a possible role for Jem-1-1 as a transcription cofactor.
Materials and methods

Reagents and vectors
LipofectAmine used for DNA transfection was purchased from GIBCO-Life Technologies (Paisley, UK). Plasmid DNA was purified using Qiagen columns (Qiagen, Courtaboeuf, France). The CAT protein quantification was carried out using a CAT-ELISA assay kit manufactured by Boehringer Mannheim (Mannheim, Germany).
Cloning of JEM-1 full length cDNA has been described previously. 50 The Jem-1-1 expression vector was constructed by inserting the cDNA fragment containing the complete ORF into a pSG5 expression vector (Stratagene, La Jolla, CA, USA). The Jem-1-⌬ 331-400 expression vector contains a Jem-1-1 insert lacking the Jem-1-1 amino-acids 331 to 400. The Jem-1-⌬ L-179-206 expression vector was made by deleting the MaeII fragment of Jem-1-1, which corresponds to the leucine repeat (amino acids 179-206). The Jem-1-pGEX expression vector was obtained by inserting the coding region of the JEM-1 cDNA fragment into a glutathione-S-transferase (GST) fusion expression vector pGEX-4T-2 (Pharmacia). The pRSV-Jun and pSV-Fos expression vectors and Coll-p(−517/+63) interstitial collagenase-CAT gene reporter vector were previously described. 52 A constitutive luciferase-expression vector (generously provided by Dr C Gazin, Paris, France) was used to normalize transfection efficiency.
Rabbit polyclonal anti-Jem-1 serum was raised against the GST-Jem-1 fusion protein generated in E. coli (pGEX expression vector) as recommended by the manufacturer (Pharmacia). Rabbits were immunised by repeated foot-pad injection at 2-week intervals of affinity-purified E. coli recombinant Jem-1-1 protein (Biocytex, Marseille, France). Monoclonal antibody against human Fos protein (Ab-1) was furnished by Calbiochem (France). Rabbit polyclonal antibody against human RAR␣ was generously given by Prof P Chambon (IGBMC, Illkirch, France) and anti-human PML protein monoclonal antibody was provided by Drs H de Thé (CNRS, Paris, France) and T Naoe (Kyoto, Japan). Monoclonal antibody against the spliceosome component SC-35 was purchased from Sigma (St Louis, MO, USA).
Cell culture, transfection, transient expression and CAT reporter gene assay
HeLa or COS-7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% bovine serum, 2 mM L-glutamine (Life Technology, Cergy, France). For CAT assays, Hela cells were transfected by LipofectAmine according to the manufacturer's procedure (Life Technology), then cultured for 48 h after which cell extracts were prepared. The expression of Jem-1-1, c-fos and c-jun proteins was induced by tranfection of the respective expression plasmids. The amount of the respective promoters was kept constant in the transfected cells by complementing with the 'empty' expression vectors. All transfections include 0.5 g of a constitutive RSV-luciferase expression vector as an internal control to normalize for transfection efficiencies. The CAT protein quantification was carried out using a CAT-ELISA assay kit (Roche Diagnostics, France).
Heparin-sepharose chromatography
Jem-1, Fos and Jun proteins were synthesized and metabolically labelled ( 35 S-methionine, Amersham, UK) by in vitro transcription-translation ('TNT' kit; Promega, Madison, WI, USA) and 20 l aliquots of proteins in PBS buffer were loaded on to a 1 ml heparin-sepharose affinity column (HiTrap; Pharmacia), previously equilibrated with at least two column volumes of PBS. Columns were then washed with five volumes of PBS and eluted with PBS containing 1 M NaCl. Washing and elution fractions were collected and concentrated to about 50 l by centrifugation (Centricon 10; Amicon, USA). Protein aliquots (10 l) in Laemmli solution were loaded on a 12% SDS-PAGE gel, electrophoresed and analyzed by autoradiography (X-Omat, Kodak, USA) or by immuno-blotting with polyclonal anti-Jem-1 antibody.
Western blot analysis
After transfer to the nitrocellulose membrane, the in vitro translated proteins were visualized with Ponceau S (Sigma) to confirm equal loading. Membranes were blocked with 5% nonfat milk, 0.2% Tween 20 in PBS pH 7.4, 137 mM NaCl, then incubated with MAb (0.1 g/ml) in PBS (or polyclonal antibody, 1:500 vol/vol), 3% nonfat milk, 0.1% Tween 20, for 18 h at 4°C. Membranes were then incubated with mouse anti-rabbit antibody conjugated with peroxidase (1:10 000) for 30 min at 25°C. All these steps were followed by three washes for 10 min in PBS, 1% nonfat milk, 0.2% Tween 20. Labelling was performed as described in the ECL protocol (Amersham, UK) using Fuji X-ray film. Figure 1c ) are identified in a single field. Cells expressing high amounts of Jem-1 showed Jem-1 accumulation in unidentified sites in the cytoplasm (cell 3) in addition to the nuclear sites. During mitosis (cell 4) the nuclear membrane is disrupted. At metaphase Jem is not found associated to mitotic chromosomes but remains in the vicinity of chromosomes (see in cell 4, the central area occupied by chromosomes in metaphase, where Jem is excluded), as large punctuated aggregates. Mitotic cells detaching from the culture surface showed long cytoplasmic extensions (pseudopodia) also positive for Jem (cell 4). (d) Mitotic figure immediately after cytokariesis. When the nuclear membrane reforms at telophase, Jem-1 relocates within the cell nucleus and after cytokariesis most of the Jem-1 protein is relocalized in the nuclei as seen above in the initial punctuated pattern.
AP-1 gel mobility shift assay
A 21-mer consensus DNA binding site for c-jun and Fos/jun heterodimer complexes (AP-1) (5Ј-CGCTTGATGACTCA-GCCGAA-3Ј) supplied by Santa-Cruz Biotech (Santa Cruz, CA, USA) was 32 P-labelled using the T4 polynucleotide kinase (New England Biolabs). Gel mobility shift assays were performed as follows: 0.3 pg of 32 P-labelled AP-1 oligonucleotide probe was pre-incubated in 50 mM NaCl; 1 mM EDTA; 1 mM DTT, 10 mM Tris buffer pH 7.5 and 6% glycerol for 10 min at 4°C, with or without unlabelled competitor oligonucleotide. 3 l aliquots of in vitro translated Jem-1-1, Jun and Fos proteins were added to the binding mixture (20 l total volume) and the samples were further incubated for 20 min at 4°C. DNA-protein complexes were resolved on 4% polyacrylamide gels equilibrated in 0.5% TBE buffer and run at 200 V. The gels were dried and autoradiographed at −80°C. The relative amounts of in vitro translated proteins loaded on the gels were determined by immunoblotting with specific antibody, or by autoradiography of the proteins labelled with 35 S-methionine during in vitro translation.
Immunohistological labelling and confocal microscope analyses
Intracellular localization of recombinant protein in transfected cells was analyzed 20 h or 48 h after transfection depending on the experiment, either on cytocentrifuge smears or directly on culture coverslips. Cells grown on coverslips were washed in PBS and fixed in methanol at −20°C for 10 min, then washed in PBS. Alternatively, cells were pelleted on to glass slides in a cyto-centrifuge (Cytospin; Shandon) at 90 g for 5 min (150 l at a cell concentration of 75 000 cells/ml) and slides were quickly air-dried. The slides were fixed in acetone at 4°C for 10 min, and dried. In single and double labelling experiments, transfected Jem-1-1 was detected with the rabbit polyclonal antisera (prepared as described above). For double labelling PML, SC-35 and Fos were detected with their respective monoclonal antibody (see Reagents and vectors). Primary antibodies were diluted in block solution and incubated with the permeabilized cells for 1-2 h at room temperature. Secondary antibodies used included a CY3-coupled antimouse antibody (Sigma) and a FITC-coupled anti-rabbit antibody (Dako, France), were incubated with cells for 30 min at room temperature. All incubations were followed by three washes in PBS followed by a final wash in PBS containing 0.05% Tween for 10 min.
Fluorescent preparations were examined by confocal laser scanning microscopy using a BioRad MRC-600 confocal imaging system (Bio-Rad Microscience, Hertfordshire, UK) and an inverted Diaphot 300 Nikon microscope. Images were collected using an oil immersion lens (60×, NA 1.4 plan Apochromat). For fluorescein and CY3 excitation a krypton/argon ion laser (Ion Laser Technology, Salt Lake City, UT, USA) operating with the 488 nm line was used. For DAPI excitation, an Entreprise ion laser (Coherent Laser Group, Santa Clara, CA, USA) operating with a 353 nm line was used. Images of FITC, CY3 and DAPI were merged and pseudo-colored green for FITC, red for CY3 and blue for DAPI. Each image represents a single section for which the confocal system was adjusted to allow a field depth of about 0.8 m.
Photographs were taken on Kodak T-Max film using a camera mounted on a VM1710 Lucius and Baer film recorder. Color pictures from screen images were taken on Fujichrome 100 with an Olympus OM-135 mm camera. CY3, red) . Note the two proteins exhibited localization in fine punctuated structures, and that some larger structures overlapped (seen as yellow color). Given the size of these bodies, we could not conclude whether this was colocalization or fluorescence overlapping. Note also that neither SC-35 nor Jem-1 were found in the nucleoli.
Results and discussion
Ectopic expression of Jem-1-1 protein
Although the JEM-1 gene transcript can be easily identified by Northern blot in most tissues, 51 the antibody so far developed lacks the specificity and sensitivity to allow detection of endogenous Jem-1 proteins. However, transient expression of Jem-1 protein in COS-7 or HeLa cells allowed us to determine Jem-1 protein localization and to explore the function of this novel nuclear factor.
To determine the intracellular localization of the Jem-1-1 protein, a full length JEM ORF cDNA inserted in a pSG5 (SV40 promoter) eukaryotic expression vector was transfected into HeLa and COS-7 cells (see Materials and methods). Figure 1a shows a speckled pattern of nuclear localization of the Jem-1-1 protein with no detectable expression in the nucleoli. Nontransfected cells in the same culture conditions did not show detectable Jem-1-1 expression. Immediately after cell transfection, at the early stage of Jem-1-1 protein synthesis (20 h), Jem-1-1 was first detected exclusively in the nucleus as multiple micro-punctuated structures (Figure 1b) . Thereafter, from 48 h, aggregation of the Jem-1 protein in larger structures occurred when the recombinant protein accumulated and covered large dots in the nucleus, as shown by densitometry analysis. In some transfected cells, the Jem-1 protein was observed in both the nuclei and the cytoplasm (Figures 1b, c  and legends) . Most of these cells expressed the Jem-1 protein abundantly, particularly in the nuclei, where densitometry measurements detected large areas highly positive for Jem-1. In these cells, cytoplasmic expression of Jem-1 showed a poorly defined punctuated pattern. Both the kinetic and the quantitative features of Jem-1 expression suggest that the cytoplasmic expression could result from either (1) protein overexpression saturating nuclear sites or the nuclear import machinery; or (2) proteolytic processing and translocation of the nuclear protein. 
Nuclear localization sites of the 45 kDa Jem-1-1 protein
Based on the features of the 45 kDa Jem-1 protein 50 and the speckled pattern of expression in nuclei reported in Figure 1 , it was of interest to determine more precisely the nuclear localization of Jem-1 with respect to other well defined nuclear markers. Double-immunofluorescent labelling with antibody against other known nuclear markers were therefore performed.
Transfected Jem-1-1 showed no colocalization with the nuclear structures called PML nuclear bodies (NBs) 53, 54 containing the endogenous PML protein (Figure 2a1 ). INF␥-induced or ectopic overexpresion of PML has previously been shown to reduce the number, but increase the size, of PML NBs, 55 a phenomenon which resembles what we have described above for Jem-1. In order to determine whether the respective localization of PML and Jem-1-1 were modified by PML overexpression, COS-7 cells were cotransfected with both the Jem-1-expressing vector and an expression vector encoding PML. Although, as described before PML overexpression modifies PML NBs which were reduced in number and increased in size (Figure 2a2, red signal) , it does not influence Jem-1-1 localization, thus confirming the no colocalization of PML and Jem-1-1 proteins.
Jem-1 was not associated with the micro-punctuated nuclear domains containing the splicing factor SC-35 [56] [57] [58] ( Figure 2b ). Jem-1 protein was found in fine punctuations, which did not contain SC-35, but occasionally when cells overexpressed Jem-1 some large punctuation containing Jem-1 also contained significant traces of SC-35 labelling.
Because of some structural homologies with nuclear factors with leucine repeats, 50 we investigated whether Jem-1 could be more specifically associated with transcription factors within the nucleus. The composite transcription factor activating protein 1 (AP-1) comprises either homodimeric (two members of the Jun family protein) or heterodimeric (one Jun and one Fos family member) factors. 59 After co-transfection of COS-7 cells with Jem-1, and c-Jun plus c-Fos (AP-1), immunocytofluorescence studies revealed that Jem-1 (identified with anti-Jem-1 antibody) and AP-1 (identified with anti-Fos antibody) were associated with the same nuclear structures (Figure 3a) . On the same slide, co-transfected cells often expressed variable amounts of Jem-1 and c-Fos proteins. When c-Fos was overexpressed compared to Jem-1, the numerous Fos-containing structures (diffuse pattern or fine punctuations) were negative for Jem-1, while some larger punctuations containing Fos were strongly positive for Jem-1. In contrast, when Jem-1 was overexpressed compared to Fos, all Jem-1-positive structures were also positive for c-Fos (Figure 3b) . This supports the hypothesis that when Jem-1 is overexpressed it compels molecular aggregation, taking AP-1 along to larger structures. Some other nuclear factors (Sp1, CBP, RAR␣) were also analyzed, but did not colocalize with Jem-1 (not shown).
Molecular interactions of Jem-1 with AP-1
To determine whether Jem-1 directly or indirectly interacts with the AP-1 complex, we first tested the effect of deleting Jem-1 of putative domains of protein interaction on its intracellular localization with AP-1, and the possibility of direct in vitro interaction with in vitro translated AP-1 components.
Interaction could occur directly by heterodimer formation (Figure 4a ) was co-transfected with c-Fos and c-Jun, and no change in nuclear localization of Jem-1 was found (Figure 4b and c) . Surprisingly, when the C-terminal domain of Jem-1 (Jem-1⌬ 331-400 ) was deleted (Figure 4a ), Jem-1 was not detected in the nuclei, but found in large punctuated structures in the cytoplasm (Figure 4d and e) . This supports the hypothesis that the C-terminus of Jem-1 contains a peptide signal(s) for nuclear translocation, or a domain of interaction with specialised carrier or nucleophilic proteins.
The possibility of a direct interaction of Jem-1 with c-Fos and c-Jun proteins was further evaluated by a DNA mobility shift assay. Jem-1, c-Fos and c-Jun were translated separately or co-translated in vitro, then incubated with the same amount of a 21-mer In vitro-translated, 35 S-methionine labelled Jem-1 protein showed a strong interaction with the polyanion heparin since 
Functional interactions with AP-1
To address the question of whether Jem-1 might have functional interaction with transcription factors, we first determined whether Jem-1 could affect AP-1 transcriptional activity, using an AP-1 CAT assay. HeLa cells were transiently transfected with expression vectors for c-Fos, c-Jun and Jem-1, combined with a CAT expression vector driven by the interstitial collagenase gene promoter. 60 We first demonstrated that Jem-1 has no transcriptional activity on this promoter containing a consensus-binding site for AP-1 (Figure 6a ). This result was expected since in vitro Jem-1 did not bind to the consensus DNA binding site of AP-1 (Figure 5a We determined whether the leucine repeat of Jem-1 could influence the enhancer capacity of Jem-1 on AP-1-dependent transcription. The leucine-repeat deleted Jem-1 expression vector (Jem-1 ⌬L-179-206 ) was used instead of total Jem-1 cDNA to transfect HeLa cells. Figure 6b shows that Jem-1 ⌬L-179-206 protein, despite the lack of the leucine repeat, retained its capacity to enhance AP-1-dependent transcription. The expression vector encoding Jem-1 deleted in the Cterminal end (Jem-1⌬ 331-400 ) was tested in parallel (Figure 6b ) and the results showed that the corresponding mutated protein had no enhancer activity.
In conclusion, JEM-1 is one of the several novel gene transcripts that have been identified by cDNA differential display in the t(15;17) APL NB4 cell line 61 induced to maturation by retinoic acid. The leukemia blast cells showed a very low expression of the 3 kb JEM-1 transcript 50 and the up-regulation of JEM-1 preceded and accompanied cell differentiation induced by retinoids. Importantly, we have recently established that JEM-1 is a ubiquitously expressed gene, from which multiple transcripts varying in size and tissue expression are generated. 51 Based on transient expression in HeLa or COS-7 cells, we conclude that (1) Jem-1-1 and AP-1 colocalize in speckled nuclear structures; and (2) Jem-1-1 exhibits no transactivation capacity on promoters containing AP-1 binding sites but acts as a potent enhancer of AP-1 activity. Despite a colocalization of Jem-1 and AP-1 proteins, when ectopically expressed, no evidence for a direct in vitro interaction has been found. We hypothesized an indirect action, Jem-1 being a component of a multimolecular complex involved in the regulation of AP-1 transcriptional activity. Since no enhancer activity on CAT gene reporters containing RARE and GRE promoters (results not shown), the functional interaction of Jem-1 with AP-1 exhibited some specificity. Therefore, further studies should determine whether Jem-1-1 specifically regulates AP1 activity, or also modulate other transcription factor activities. Interestingly also, JEM-1 may function as a structural component of the nucleoplasm involved in transcription, or as a novel cofactor interacting with the basal transcription machinery.
At this stage it is far too early to speculate on any possible function of Jem-1 on APL cell maturation, or on cell differentiation in general. Nevertheless, the wide spectrum of action of AP1 in cell proliferation, cell differentiation and cell death offers interesting prospects. Considering on the one hand, the transcriptional activity of AP-1, believed to reflect cell proliferation in many tissues in response to extracellular (mitogenic) factors, and on the other hand, the diverse reciprocal interaction (cross-modulation that AP-1 develops with other nuclear factors), 17 an AP-1 enhancer becomes a nuclear factor of interest in the myeloid leukemia cell maturation [62] [63] [64] and in the APL response to retinoids in particular. 46 
